Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours

Journal of Surgical Oncology

Volumn 92, Issue 4, 2005, Pages 337-343

  Fauvet, Raffaèle ^a,b   Dufournet, Charlotte ^a   Poncelet, Christophe ^b   Uzan, Catherine ^a   Hugol, Danièle ^c   Daraï, Emile ^a,b  

^a HÔPITAL TENON   (France)

^b BICHAT HOSPITAL   (France)

^c HÔTEL DIEU   (France)

Author keywords

Apoptosis; Immunohistochemistry; Ovarian cancer; Serous and mucinous ovarian tumours; Tumour of low malignant potential

Indexed keywords

FAS ANTIGEN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 28844485350     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20424     Document Type: Article

References (38)

1. Seidman JD, Kurman RJ: Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;5:539-557.
2. Taylor HC: Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstet 1929;48:204-230.
3. International federation of Gynecology and Obstetrics: Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1-7.
4. Serov SF, Scully RE, Sobin LH: Histologic typing of ovarian tumors, in International Histological Classification and Staging of Tumors (no 9). Geneva, Switzerland: World Health Organization, 1973.
5. Bostwick DG, Tazelaar HD, Ballon SC, et al.: Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986;58:2052-2065.
6. Feeley KM, Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
7. Wells M, Hutson R: Candidate precursors lesions. In: Sharp F. Blackett T, Leake R, Berek J, editors. Ovarian cancer 4. London: Chapman and Hall medical. 1996, 27-35.
8. Godwin AK, Testa JR, Hamilton TC: The biology of ovarian cancer development. Cancer 1993;71:530-536.
9. Plaxe SC, Deligdisch L, Dottino PR, et al.: Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 1990;38:367-372.
10. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, et al.: Contralateral ovary in unilateral ovarian carcinoma: A search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63.
11. Tresserra F, Grases PJ, Labastida R, et al.: Histological features of the contralateral ovary in patients with unilateral ovarian cancer: A case control study. Gynecol Oncol 1998;71:437-441.
12. Resta L, Russo S, Colucci GA, et al.: Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993;82:181-186.
13. Werness BA, Freedman AN, Piver MS, et al.: Prognostic significance of p53 and p21 (waf1/cip1) immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 1999;75:413-418.
14. Dubeau L: The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol Oncol 1999;72:437-442.
15. Hsu SY, Hsueh AJ: Tissue-specific Bcl-2 protein partners in apoptosis: An ovarian paradigm. Physiol Rev 2000;80:593-614.
16. Kupryjanczyk J, Bell DA, Dimeo D, et al.: p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:387-392.
17. Klemi PJ, Takahashi S, Joensuu H, et al.: Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-233.
18. Lee JH, Kang YS, Park SY, et al.: P53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995;85:43-50.
19. Chan WY, Cheung KK, Schorge JO, et al.: Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000;156:409-417.
20. Zusman I, Gurevich P, Gurevich E, et al.: The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors (a review). Int J Oncol 2001;18:965-972.
21. Wehrli BM, Krajewski S, Gascoyne RD, et al.: Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors. Int J Gynecol Pathol 1998;17:255-260.
22. Munakata S, Enomoto T, Tsujimoto M, et al.: Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000;82:1446-1452.
23. Ben-Hur H, Gurevich P, Huszar M, et al.: Apoptosis and apoptosis-related proteins in the epithelium of human ovarian tumors: immunohistochemical and morphometric studies. Eur J Gynaecol Oncol 1999;20:249-253.
24. Oncology Committee of the International Federation of Gynecology and Obstetrics: Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987;156:263-264.
25. Gershenson DM.: Contemporary treatment of borderline ovarian tumors. Cancer Invest 1999;17:206-210.
26. Darai E, Walker-Combrouze F, Mlika-Cabanne N, et al.: Expression of p53 protein in borderline epithelial ovarian tumors: A clinicopathologic study of 39 cases. Eur J Gynaecol Oncol 1998;19:144-149.
27. Cao L, Yang Z, Li X.: Expression and significance of tumor suppressor gene WAF1 in epithelial ovarian neoplasms. Hunan Yi Ke Da Xue Xue Bao 1998;23:602-604.
28. Gottlieb TM, Oren M: P53 and apoptosis. Semin Cancer Biol 1998;8:359-368.
29. Deng C, Zhang P, Harper JW, et al.: Mice lacking p21CIPI/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
30. Brugarolas J, Chandrasekaran C, Gordon JI, et al.: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-557.
31. Attardi LD, Lowe SW, Brugarolas J, et al.: Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 1996;15:3693-3701.
32. Vaux Dl, Cory S, Adams Jm: Bcl-2 gene promotes haematopoetic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
33. Henriksen R, Wilander E, Oberg K: Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-1329.
34. Athanassiadou P, Petrakakou E, Sakelariou V, et al.: Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours. Eur J Cancer Prev 1998;7:225-231.
35. Yin C, Knudson CM, Korsmeyer SJ, et al.: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997;385:637-640.
36. Knudson CM, Tung KS, Tourtellotte WG, et al.: Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96-99.
37. McCurrach ME, Connor TM, Knudson CM, et al.: Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997;94:2345-2349.
38. Witty JP, Jensen RA, Johnson AL: Expression and localization of Bcl-2 related proteins in human ovarian cancers. Anticancer Res 1998;18:1223-1230.